Developer docs
API playgroundTry for free, no card

Search company profiles

AGIC Capital

Full company profile

uuid0000x5q

Namestring
AGIC Capital
Legal namestring
AGIC Partners GmbH
Websiteurl
agic-group.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

AGIC Capital is a growth-oriented European-Asian private equity firm founded in 2015 by Henry Cai (former Deutsche Bank and UBS Asia investment banking chairman) and headquartered in Munich, Germany. The firm manages US$2.2 billion in assets under management across two blind-pool funds — Fund I (US$1.0 billion, final close February 2017) and Fund II (US$1.2 billion, final close September 2021) — and invests between €50-250 million per company in majority and significant minority transactions targeting enterprise values of US$50-500 million. Its investment thesis targets two verticals: advanced industrial technology (engineered products and systems, specialty materials and chemicals, B2B distribution) and healthcare technology (medical devices and consumables, life science tools and services, CDMO/CRO, regulatory and quality). The firm's defining proposition is hands-on cross-border value creation, helping European-headquartered mid-market companies expand into Asian markets — particularly China — through local teams in Hong Kong, Shanghai and Beijing, a bench of senior industry advisors, and operational support covering go-to-market, pricing, salesforce effectiveness, and add-on M&A.

AGIC generates revenue through management fees and carried interest on its investment funds, with capital sourced from institutional investors including family offices, pension funds and sovereign wealth funds; Fund II was largely subscribed by existing LPs re-upping from Fund I. The firm has executed approximately fifteen platform deals and six disclosed exits over a decade, including Gimatic (sold to Barnes Group for €370 million in 2018), KraussMaffei Group (IPO and subsequent sale to ChemChina), Fotona (sold to Vitruvian Partners in 2021 with AGIC reinvesting), Ritedose (sold to Novo Holdings in 2022), Farsound (sold to Onex in August 2024) and Compart (exited July 2025). Current and recent portfolio companies span industrial automation (Gimatic, PR Electronics), medical devices (Fotona, AP Technologies), pharmaceutical manufacturing (Ritedose, ATEC Pharmatechnik), aerospace MRO supply chain (Farsound), lithography (Eulitha), roll-to-roll and EV battery manufacturing (Grafotronic), premium packaging (Pure Trade), dental consumables (Solmetex) and thin-film coatings (Soleras). The firm operates with 25+ investment professionals across six offices — Munich (headquarters), London, Paris, Hong Kong, Shanghai and Beijing — supported by senior advisors including former executives of GE, NXP, Porsche, Mycronic, Manz AG, Swisslog, Knorr-Bremse and a former German Minister of Economics.

Short descriptiontext

AGIC Capital is a Munich-headquartered European-Asian private equity firm with US$2.2B AUM, investing €50–250M per deal in advanced industrial and healthcare technology companies with a focus on cross-border expansion into Asian markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMunich, Germany
HQ citystring
Munich
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
private equity investments, growth capital, industrial technology, healthcare investments, cross-border M&A
Industry3 codes
PRIMARYFSANACAM
Agriculture & Food / AgTech Growth Equity
SECONDARYBPAHAOAE
Equity Capital Advisory (Private Equity Placements, Growth Capital)
SECONDARYBPAHADAB
Corporate Finance & Capital Advisory
NAICS code4 codes
  • Other Financial Vehicles52599
  • Other Investment Pools and Funds5259
  • Portfolio Management and Investment Advice523940
  • Other Financial Investment Activities5239
SIC code3 codes
  • Investors, Nec6799
  • Security Brokers, Dealers & Flotation Companies6211
  • Investment Advice6282
Product category
Private Equity Investment Management
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Private Equity Returns
TypeManaged Services
Description

AGIC Capital generates returns through management fees and carried interest from its investment funds. Fund II raised US$1.2 billion, reflecting investor appetite for their investment strategy.

agic-group.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

AGIC Capital is a private equity firm that manages investment funds providing growth capital of €50–250 million per transaction to mid-market European companies in advanced industrial technology and healthcare technology sectors. It acquires majority and minority equity stakes and works hands-on with portfolio company management teams to execute international growth strategies, particularly expansion into Asian markets. The firm generates returns through capital appreciation, exits via trade sales or IPOs, and supporting add-on M&A within portfolio companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Successful exits from 6 investments including Gimatic (€370M to Barnes Group), KraussMaffei Group (IPO), Fotona (to Vitruvian), Farsound (to Onex), Soleras, and Ritedose (to Novo Holdings)
Product overview1 text field

AGIC Capital is a private equity firm, not a product or technology company. It does not offer products or services in the traditional sense. The firm manages investment funds and acquires stakes in portfolio companies across advanced industrial technology and healthcare technology sectors. AGIC Capital's portfolio includes companies such as AP Technologies (medical device contract manufacturing), Pure Trade (premium packaging supply chain), PR Electronics (signal conditioning devices), ATEC Pharmatechnik (aseptic processing solutions), Fotona (medical laser systems), Farsound (aerospace supply chain), Eulitha (nano-UV lithography equipment), Grafotronic (roll-to-roll automated manufacturing solutions), Gimatic (industrial automation components), KraussMaffei (plastics/rubber processing machinery), Ritedose (pharmaceutical BFS manufacturing), Compart (gas delivery systems), and Soleras (sputtering targets and equipment). These are portfolio company investments, not AGIC Capital's own products.

Product and service4 records
1AGIC Fund I
CategoryPrivate Equity Fund
Description

AGIC's first private equity fund, a US$1 billion blind-pool vehicle that invests majority and minority equity into European small- and mid-cap companies in intelligent manufacturing, high-end equipment, advanced materials, medical technologies, and environmental protection technologies, with a focus on supporting portfolio companies' expansion into Asian markets, particularly China. The fund is offered to qualified institutional investors.

2AGIC Fund II
CategoryPrivate Equity Fund
Description

AGIC's second private equity fund, a US$1.2 billion blind-pool vehicle that makes majority and significant minority investments with enterprise values typically in the range of US$50–500 million in advanced industrial and medical technology companies in Europe and beyond. The fund is offered to qualified institutional investors and re-ups with existing LPs from Fund I.

3Growth Capital Investments in Advanced Industrial Technology
CategoryPrivate Equity Investment
Description

Equity capital and hands-on operational support for European mid-market companies in engineered products & systems, specialty materials & chemicals, and B2B distribution sectors, with cheque sizes between €50–250 million per company and enterprise values of €100–500 million.

4Growth Capital Investments in Healthcare & Life Sciences Technology
CategoryPrivate Equity Investment
Description

Equity capital and hands-on operational support for European mid-market companies in medical devices & consumables, life science tools & services, and specialty healthcare services (CDMO, CRO, regulatory compliance & quality) sectors, with cheque sizes between €50–250 million per company.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

European-Asian cross-border private equity firm with parallel thesis of bridging Western mid-market companies with Asia growth. Closest direct competitor in size, geography, and sector focus.

TypeDirect peer
Description

Asia-focused private equity firm (formerly Standard Chartered Private Equity) investing in mid-market companies across Asia with similar cross-border value creation approach.

TypeDirect peer
Description

European mid-market private equity firm with strong industrial technology and healthcare/life sciences exposure, comparable AUM scale and sector overlap.

TypeDirect peer
Description

Healthcare-focused middle-market private equity firm, comparable in check size and healthcare technology investment thesis.

TypeDirect peer
Description

European mid-market private equity firm with comparable deal size, industrial and healthcare sector focus, and growth-oriented investment approach.

TypeDirect peer
Description

Asia-focused private equity firm with significant cross-border China investment activity and comparable mid-market industrial exposure.

TypeDirect peer
Description

European mid-market private equity firm with strong industrial and B2B services focus, comparable investment size and sector concentration.

TypeRegional player
Description

Southeast Asia-focused growth equity firm with comparable mid-market investment size and consumer/industrial sector breadth, though Asia-only focus.

TypeBroad incumbent
Description

Major European private equity firm with significant healthcare and industrial technology exposure at scale, representing a broader incumbent in the same sectors.

TypeBroad incumbent
Description

Large European private equity firm with healthcare and industrial technology investment activities, providing broader incumbent comparison for sector and deal-size overlap.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles20 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A9 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment5 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AGIC Capital

Private Equity Investment Managementagic-group.com

AGIC Capital is a Munich-headquartered European-Asian private equity firm with US$2.2B AUM, investing €50–250M per deal in advanced industrial and healthcare technology companies with a focus on cross-border expansion into Asian markets.

What AGIC Capital does

AGIC Capital is a growth-oriented European-Asian private equity firm founded in 2015 by Henry Cai (former Deutsche Bank and UBS Asia investment banking chairman) and headquartered in Munich, Germany. The firm manages US$2.2 billion in assets under management across two blind-pool funds — Fund I (US$1.0 billion, final close February 2017) and Fund II (US$1.2 billion, final close September 2021) — and invests between €50-250 million per company in majority and significant minority transactions targeting enterprise values of US$50-500 million. Its investment thesis targets two verticals: advanced industrial technology (engineered products and systems, specialty materials and chemicals, B2B distribution) and healthcare technology (medical devices and consumables, life science tools and services, CDMO/CRO, regulatory and quality). The firm's defining proposition is hands-on cross-border value creation, helping European-headquartered mid-market companies expand into Asian markets — particularly China — through local teams in Hong Kong, Shanghai and Beijing, a bench of senior industry advisors, and operational support covering go-to-market, pricing, salesforce effectiveness, and add-on M&A.

AGIC generates revenue through management fees and carried interest on its investment funds, with capital sourced from institutional investors including family offices, pension funds and sovereign wealth funds; Fund II was largely subscribed by existing LPs re-upping from Fund I. The firm has executed approximately fifteen platform deals and six disclosed exits over a decade, including Gimatic (sold to Barnes Group for €370 million in 2018), KraussMaffei Group (IPO and subsequent sale to ChemChina), Fotona (sold to Vitruvian Partners in 2021 with AGIC reinvesting), Ritedose (sold to Novo Holdings in 2022), Farsound (sold to Onex in August 2024) and Compart (exited July 2025). Current and recent portfolio companies span industrial automation (Gimatic, PR Electronics), medical devices (Fotona, AP Technologies), pharmaceutical manufacturing (Ritedose, ATEC Pharmatechnik), aerospace MRO supply chain (Farsound), lithography (Eulitha), roll-to-roll and EV battery manufacturing (Grafotronic), premium packaging (Pure Trade), dental consumables (Solmetex) and thin-film coatings (Soleras). The firm operates with 25+ investment professionals across six offices — Munich (headquarters), London, Paris, Hong Kong, Shanghai and Beijing — supported by senior advisors including former executives of GE, NXP, Porsche, Mycronic, Manz AG, Swisslog, Knorr-Bremse and a former German Minister of Economics.

AGIC Capital firmographics

Firmographics
Name
AGIC Capital
Legal name
AGIC Partners GmbH
Website
https://agic-group.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
AGIC Capital is a Munich-headquartered European-Asian private equity firm with US$2.2B AUM, investing €50–250M per deal in advanced industrial and healthcare technology companies with a focus on cross-border expansion into Asian markets.
Ownership category
akta.pro rank

AGIC Capital industry classification

Industry
Product category
Private Equity Investment Management
NAICS
Other Financial Vehicles (52599), Other Investment Pools and Funds (5259), Portfolio Management and Investment Advice (523940), Other Financial Investment Activities (5239)
SIC
Investors, Nec (6799), Security Brokers, Dealers & Flotation Companies (6211), Investment Advice (6282)
akta.pro industry
PRIMARYFSANACAM
Agriculture & Food / AgTech Growth Equity
SECONDARYBPAHAOAE
Equity Capital Advisory (Private Equity Placements, Growth Capital)
SECONDARYBPAHADAB
Corporate Finance & Capital Advisory

Keywords

  • Private equity investments
  • Growth capital
  • Industrial technology
  • Healthcare investments
  • Cross-border M&A

Where AGIC Capital is headquartered

Location

Headquarters

HQ city
Munich
HQ country
Germany
HQ region
Europe

Offices6 records

Markets served

AGIC Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Private Equity Returns: AGIC Capital generates returns through management fees and carried interest from its investment funds. Fund II raised US$1.2 billion, reflecting investor appetite for their investment strategy.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

AGIC Capital product offering

Product offering

Core offering

AGIC Capital is a private equity firm that manages investment funds providing growth capital of €50–250 million per transaction to mid-market European companies in advanced industrial technology and healthcare technology sectors. It acquires majority and minority equity stakes and works hands-on with portfolio company management teams to execute international growth strategies, particularly expansion into Asian markets. The firm generates returns through capital appreciation, exits via trade sales or IPOs, and supporting add-on M&A within portfolio companies.

Product overview

AGIC Capital is a private equity firm, not a product or technology company. It does not offer products or services in the traditional sense. The firm manages investment funds and acquires stakes in portfolio companies across advanced industrial technology and healthcare technology sectors. AGIC Capital's portfolio includes companies such as AP Technologies (medical device contract manufacturing), Pure Trade (premium packaging supply chain), PR Electronics (signal conditioning devices), ATEC Pharmatechnik (aseptic processing solutions), Fotona (medical laser systems), Farsound (aerospace supply chain), Eulitha (nano-UV lithography equipment), Grafotronic (roll-to-roll automated manufacturing solutions), Gimatic (industrial automation components), KraussMaffei (plastics/rubber processing machinery), Ritedose (pharmaceutical BFS manufacturing), Compart (gas delivery systems), and Soleras (sputtering targets and equipment). These are portfolio company investments, not AGIC Capital's own products.

Differentiator

Problem solved

Functional benefit

Products and services

  • AGIC Fund I AGIC's first private equity fund, a US$1 billion blind-pool vehicle that invests majority and minority equity into European small- and mid-cap companies in intelligent manufacturing, high-end equipment, advanced materials, medical technologies, and environmental protection technologies, with a focus on supporting portfolio companies' expansion into Asian markets, particularly China. The fund is offered to qualified institutional investors.
  • AGIC Fund II AGIC's second private equity fund, a US$1.2 billion blind-pool vehicle that makes majority and significant minority investments with enterprise values typically in the range of US$50–500 million in advanced industrial and medical technology companies in Europe and beyond. The fund is offered to qualified institutional investors and re-ups with existing LPs from Fund I.
  • Growth Capital Investments in Advanced Industrial Technology Equity capital and hands-on operational support for European mid-market companies in engineered products & systems, specialty materials & chemicals, and B2B distribution sectors, with cheque sizes between €50–250 million per company and enterprise values of €100–500 million.
  • Growth Capital Investments in Healthcare & Life Sciences Technology Equity capital and hands-on operational support for European mid-market companies in medical devices & consumables, life science tools & services, and specialty healthcare services (CDMO, CRO, regulatory compliance & quality) sectors, with cheque sizes between €50–250 million per company.

Quantifiable outcome

  • Successful exits from 6 investments including Gimatic (€370M to Barnes Group), KraussMaffei Group (IPO), Fotona (to Vitruvian), Farsound (to Onex), Soleras, and Ritedose (to Novo Holdings)

Companies that use AGIC Capital

Customer profile

Named customers8 records

Segments2 records

Ideal customer profiles2 records

AGIC Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AGIC Capital partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves11 records

Expansion highlights6 records

AGIC Capital competitors and assessment

Company assessment

Direct peers

  • Cathay Capital: European-Asian cross-border private equity firm with parallel thesis of bridging Western mid-market companies with Asia growth. Closest direct competitor in size, geography, and sector focus.
  • Affirma Capital: Asia-focused private equity firm (formerly Standard Chartered Private Equity) investing in mid-market companies across Asia with similar cross-border value creation approach.
  • Gimv: European mid-market private equity firm with strong industrial technology and healthcare/life sciences exposure, comparable AUM scale and sector overlap.
  • Avista Capital Partners: Healthcare-focused middle-market private equity firm, comparable in check size and healthcare technology investment thesis.
  • IK Partners: European mid-market private equity firm with comparable deal size, industrial and healthcare sector focus, and growth-oriented investment approach.
  • Baring Private Equity Asia: Asia-focused private equity firm with significant cross-border China investment activity and comparable mid-market industrial exposure.
  • Triton Partners: European mid-market private equity firm with strong industrial and B2B services focus, comparable investment size and sector concentration.

Regional players

  • Creador: Southeast Asia-focused growth equity firm with comparable mid-market investment size and consumer/industrial sector breadth, though Asia-only focus.

Broad incumbents

  • EQT Partners: Major European private equity firm with significant healthcare and industrial technology exposure at scale, representing a broader incumbent in the same sectors.
  • Permira: Large European private equity firm with healthcare and industrial technology investment activities, providing broader incumbent comparison for sector and deal-size overlap.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

AGIC Capital social profiles

Digital presence

AGIC Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AGIC Capital leadership team

Management profile

Number of profiles

Profiles20 records

AGIC Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AGIC Capital M&A and investment

M&A and investment

M&A9 records

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AGIC Capital

What does AGIC Capital do?

AGIC Capital is a private equity firm that manages investment funds providing growth capital of €50–250 million per transaction to mid-market European companies in advanced industrial technology and healthcare technology sectors. It acquires majority and minority equity stakes and works hands-on with portfolio company management teams to execute international growth strategies, particularly expansion into Asian markets. The firm generates returns through capital appreciation, exits via trade sales or IPOs, and supporting add-on M&A within portfolio companies.

Is AGIC Capital a public or private company?

AGIC Capital is a private company. It is classified as management employee owned and is currently operating.

When was AGIC Capital founded?

AGIC Capital was founded in 2015. It employs 11 to 50 people.

Where is AGIC Capital based?

AGIC Capital is headquartered in Munich, Germany, in the Europe region.

How does AGIC Capital make money?

One revenue line is on record: private Equity Returns.

Who are AGIC Capital's main competitors?

Direct peers on record are Cathay Capital, Affirma Capital, Gimv, Avista Capital Partners, IK Partners, Baring Private Equity Asia and Triton Partners. Creador is listed as a regional player. Broad incumbents are EQT Partners and Permira.

Does AGIC Capital have an API?

No public API is recorded for AGIC Capital.

What industry is AGIC Capital in?

AGIC Capital's product category is Private Equity Investment Management. Its primary akta.pro industry code is FSANACAM, Agriculture & Food / AgTech Growth Equity, with a secondary code of BPAHAOAE, Equity Capital Advisory (Private Equity Placements, Growth Capital). Its NAICS code is 52599 and its SIC code is 6799.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AETOSWireAGIC Capital Acquires Majority Stake in ATEC Pharmatechnik GmbHAGIC Capital acquired a majority stake in ATEC Pharmatechnik GmbH, a manufacturer of aseptic processing solutions for pharmaceutical and bioprocessing applications. The sellers, founder Hans-Werner Mumm and HANNOVER Finanz Group, will remain invested, with Mumm continuing as CEO. This is expected to be the first of several acquisitions as AGIC builds a specialty process technologies platform.YahooAvista Healthcare Partners Completes Sale of Solmetex to AGIC CapitalAvista Healthcare Partners completed the sale of Solmetex to AGIC Capital, retaining a minority stake. The transaction terms were not disclosed, and Solmetex's CEO expressed gratitude for Avista's support. AGIC Capital and Avista will continue to support Solmetex's growth.PR NewswireAvista Healthcare Partners Completes Sale of Solmetex to AGIC CapitalAvista Healthcare Partners completed the sale of Solmetex to AGIC Capital, retaining a minority stake. The transaction terms were not disclosed, and Avista highlighted three strategic acquisitions during its partnership. Solmetex will continue with AGIC Capital as its new partner.CityNews TorontoOnex signs deal for aircraft parts supplier Farsound AviationOnex Corp. signed a deal to acquire Farsound Aviation, a British aircraft parts supplier, from private equity firm AGIC Capital. Financial terms were not disclosed, and the deal is expected to close later this year subject to regulatory approvals.Business Wire BlogAGIC Capital Completes Growth Equity Investment into AP TechnologiesAGIC Capital completed a growth equity investment into Singapore-based AP Technologies, an emerging medical device contract manufacturer specializing in precision medical tubing and catheter assemblies. The investment, of an undisclosed amount, marks AGIC's first transaction in Asia with its Fund II. The deal aims to accelerate AP Tech's global growth and promote its medical tubing products.Business Wire BlogAGIC Capital Acquires Majority Stake in Pure TradeAGIC Capital acquired a majority stake in Pure Trade, a Paris-based packaging solutions provider, from Sparring Capital and the management team. The deal marks AGIC's first transaction in France and aims to accelerate Pure Trade's expansion into the US and APAC markets.Agic-GroupAGIC Capital Completes Investment into PR Electronics in Partnership with Kirk Kapital – AGIC CapitalAGIC Capital and Kirk Kapital have completed the acquisition of PR Electronics A/S, a global supplier of signal conditioning devices for the process and factory automation industries. The transaction involves reinvestment by former CEO Kim Rasmussen and allows PR Electronics to pursue further growth through acquisitions under its existing management team. The company generates approximately DKK 437 million in annual revenue and operates with production facilities in Denmark.BioSpaceAGIC Capital Acquires Majority Stake in ATEC Pharmatechnik GmbHAGIC Capital acquired a majority stake in ATEC Pharmatechnik GmbH, a German manufacturer of aseptic processing solutions for pharmaceutical applications. The sellers, founder Hans-Werner Mumm and HANNOVER Finanz Group, will remain invested, with Mumm continuing as CEO. AGIC plans this as the first of several acquisitions to build a specialty process technologies platform.Business Wire IndiaAGIC Capital Acquires Majority Stake in ATEC Pharmatechnik GmbHAGIC Capital has acquired a majority stake in ATEC Pharmatechnik GmbH, a German manufacturer of aseptic processing solutions for the pharmaceutical industry. The transaction was supported by existing investors HANNOVER Finanz Group and founder Hans-Werner Mumm, who will remain invested with Mumm continuing as CEO. This acquisition marks the beginning of AGIC's strategy to build a specialty process technologies platform focused on pharmaceutical and biopharmaceutical markets.Agic-GroupAGIC Capital Completes Investment into Eulitha AG – AGIC CapitalAGIC Capital has invested in Eulitha AG, a Switzerland-based provider of non-contact Nano-UV-Lithography equipment and services. The investment aims to accelerate Eulitha's global growth and promote its proprietary PHABLE™ technology in various industries, including AR/VR. The partnership is expected to enhance Eulitha's market reach and financial resources to develop and market its unique technologies.